AIDS.GOV | SERVICE LOCATOR | SEARCH

BLOG.AIDS.GOV

MENU

Clinical Trials

HIV Vaccine Research: Update from NIH’s Dr. Dieffenbach from 2nd Day of AIDS 2016

Carl day 2 FB Live resized

As the second day of the International AIDS Conference (AIDS 2016) came to a close in Durban, South Africa, we caught up with Dr. Carl Dieffenbach again via Facebook Live to get his thoughts on some of the day’s highlights. He is Director of the Division of AIDS at NIH’s National Institute of Allergy and…

Vaginal Ring May Cut HIV Infection Risk if Used Consistently

Vaginal ring - cropped July 2016

NIH Clinical Trial Will Clarify Relationship between Ring Adherence, HIV Infection Risk A new exploratory analysis of data from the ASPIRE study has found that using a drug-infused vaginal ring most or all of the time reduced the risk of HIV infection in women by at least 56 percent. This finding is being reported today…

Vaginal Ring Provides Partial Protection from HIV in Large Multinational Trial

Woman holding the dapivirine vaginal ring tested in the NIH-funded ASPIRE study.
Credit: International Partnership for Microbicides

NIH-Funded Study Finds Protective Effect Strongest in Women over Age 25 A ring that continuously releases an experimental antiretroviral drug in the vagina safely provided a modest level of protection against HIV infection in women, a large clinical trial in four sub-Saharan African countries has found. The ring reduced the risk of HIV infection by…

NIH’s Dr. Carl Dieffenbach Shares Highlights as IAS 2015 Begins

IAS2015 logo crop2

After the 8th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2015) got underway in Vancouver, Canada yesterday, July 20, we spoke by Skype with Dr. Carl Dieffenbach, Director of the Division of AIDS at NIH’s National Institute of Allergy and Infectious Diseases (NIAID). He shared some highlights from the first full…

A Conversation with Dr. Anthony Fauci: Results from the START Trial and Implications for the Global Treatment of HIV

Anthony Fauci

Last week, NIH’s National Institute of Allergy and Infectious Diseases (NIAID) released the exciting results of the Strategic Timing of Antiretroviral Treatment (START) study, a randomized, controlled clinical trial to more clearly define the optimal time and benefits for people with HIV to begin antiretroviral therapy (ART). Given the implications of the study, AIDS.gov sat…

International Study Demonstrates Benefits of Early HIV Treatment

Dr. Anthony Fauci

The question of when to initiate antiretroviral therapy (ART) during the course of HIV infection has been debated for years, yet a conclusive answer has remained elusive. For HIV-infected individuals the primary question was whether to start ART early, risking possible cumulative drug toxicities, potential viral resistance, and difficulties with long-term adherence, or to defer…

New! NIH Clinical Trials Media Player Now Available

NIH media player

Clinical Trials Clinical trials play an immensely important role in finding medical advancements and developing treatments for many diseases and conditions, including HIV. The goal of clinical trials is to determine if a new test or treatment works and is safe. Clinical trials can also look at other aspects of care, such as improving quality…

New NIH Study to Tackle Cardiovascular Heart Disease in HIV-infected Individuals

REPRIEVE trial logo

If you are HIV positive and on antiretroviral therapy (ART), are you doing all you can to maintain and improve your health?  While early diagnosis of HIV infection and use of combination ART has significantly reduced AIDS-related mortality and morbidity in the U.S., it does not completely return you to your pre-infection health status. For…